
Daily Derm Times: August 18, 2025
Key Takeaways
- Pediatric psoriasis requires early intervention and awareness of comorbidities due to its unique treatment challenges.
- Dusquetide's orphan drug designation for Behçet’s Disease provides Soligenix with regulatory and financial advantages.
Catch up on dermatology news, highlights, and insights from the past 24 hours.
To stay up-to-date with the latest dermatology news, sign up to receive our
Recognizing the Hidden Burdens of Pediatric Psoriasis
Pediatric psoriasis poses unique treatment challenges, highlighting the importance of early intervention and awareness of comorbidities in young patients.
FDA Grants Orphan Drug Designation to Dusquetide for Behçet’s Disease
Orphan designation provides Soligenix with potential regulatory, financial, and exclusivity benefits as it develops SGX945.
How Dr. Rossi DERM MD Skin Care Combats Inflammatory Aging
Discover Anthony Rossi, MD, FAAD, FACMS's innovative skin care line targeting inflammatory aging with clinical science, clean formulations, and effective anti-aging solutions.
POLL: What Aesthetic Trends Are You Seeing in Gen Z and Millennial Patients?
Answer today's poll and explore the evolving aesthetic trends among Millennials and Gen Z, focusing on their unique preferences for skin care, fillers, and Botox treatments.
Vitiligo Management in Practice: Expert Case Reviews
Ted Lain, MD, MBA, moderated a Case-Based Roundtable event to discuss diverse case presentations of vitiligo and how to build a treatment regimen.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


















